

(51) International Patent Classification ⁴ : A61K 7/08, 7/06		A1	(11) International Publication Number: WO 88/ 00041 (43) International Publication Date: 14 January 1988 (14.01.88)
(21) International Application Number: PCT/EP87/00372 (22) International Filing Date: 7 July 1987 (07.07.87) (31) Priority Application Number: 8601762 (32) Priority Date: 7 July 1986 (07.07.86) (33) Priority Country: NL (71)(72) Applicant and Inventor: LANGE, Bouke, Jan [NL/NL]; Kalmoes 8, NL-2811 EB Reeuwijk (NL). (74) Agent: RHIJNSBURGER, J., G.; 's-Gravenbroekseweg 32, NL-2811 GE Reeuwijk (NL). (81) Designated States: AT, AT (European patent), AU, BE (European patent), BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB, GB (European patent),		HU, IT (European patent), JP, KR, LK, LU, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL, NL (European patent), NO, RO, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: A TWO PHASE CLEANSING, CONDITIONING AND MEDICINAL TREATMENT SHAMPOO			
(57) Abstract Two phase shampoo allowing sequential application of noncompatible substances/conditions. Two phase shampoo, especially for controlling dandruff, wherein the first phase consists of a detergent composition, together with possible adjuvants, having a neutral or alkaline pH and the second phase, separated from the first phase, comprises a physiologically acceptable acid component, of mixture of such components, which phase is applied immediately after the treatment of the hair and the skin of the head with the first phase. Both phases may contain an antimycotic. The invention also comprises a process for treating the hair and the skin of the head in two phases, using a package wherein both phases are contained separately but in a combined form.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

A two phase cleansing, conditioning and medicinal treatment shampoo.

The invention generally relates to a process for cleansing and conditioning (keeping in a good shape) of hair and skin of the head, within the context of periodically necessary hygienic, cosmetic or medicinal treatment of the hair and skin of the head.

The invention particularly relates to the control of dandruff and similar scale forming conditions of the skin of the head, as well as a two-phase shampoo for this purpose as well as ^{a)} packing therefore.

The invention will now be described with the emphasis on the last variant but is not restricted thereto.

Although the etiology of dandruff is not yet completely elucidated there are strong indications that yeast infections, such as by pityrosporum yeasts play an important role. Although yeast cells like Pityrosporum ovale or orbiculare are normally found on the skin, some people do have dandruff while others don't. For the cleansing of the hair and scalp and the elimination of dandruff one normally uses a shampoo, which in general consists of a detergent and other components, which give certain properties to shampoo. The basic component is a detergent which by its fat solubilizing ability and the rinsability with water is able to cleanse the scalp and the hair. However, it is not possible to completely eradicate dandruff by such a shampoo. The flakes are indeed largely eliminated but after a relatively short period new dandruff scales are developing, possibly by the influence of microbial metabolic products (for

example microbial toxins). The control by anti mycotics over longer periods of time involves disadvantages in connection with possible toxic contra-indications or the development of resistance by the dermatophytes. Equally treatment with means to retard cell proliferation or cell division is not advisable, since the excessive corneocyte production and scaling is probably a consequence of pathogenesis resulting from the said infection process and not the cause of dandruff (see: The aetiology of dandruff and the mode of action of therapeutic agent; S. Shuster; British Journal of Dermatology; 1984, 281, pages 235:242). It would be desirable if one could have at one's disposal a process and shampoo composition enabling one to combine the normal cleansing and conditioning of the hair and scalp with an effective method to eradicate dandruff, without making use of toxic and resistance-inducing anti-mycotic or cytostatic substances.

The invention is intended to provide such a process as well as a shampoo composition by which control of dandruff and related scaling conditions is possible without the complications mentioned.

It is known that by cleansing the hair and scalp with detergents (soaps, anionic and non-ionic detergents) the physiological and biological equilibrium of the epidermis and especially the natural pH (acidity) of the epidermis is affected (see: C.E. Orfanos - Haar und Haarkrankheiten, Gustav Fischer Verlag, 1979, especially page 955 and Biology of Hair, Tatsugi Kobori and William Montagna, 1975, page 598). The process and shampoo composition of the present invention is aimed at restoration of this equilibrium and a consecutive neutralisation of the potentially damaging effect of the cleansing procedure and dandruff control.

The invention now provides a process and associated shampoo composition by which the skin of the head and the hair is treated in two phases; on the one hand to cleanse, condition and/or control yeast growth as is shown in the main embodiment in the first phase and on the other hand for recovery and consolidation in the second phase of the equilibrium which is destroyed by the detergents etc. Both treatments are carried out separately and consecutively, but as will be understood carried out in a synergistic combination.

Thus the invention provides a process for treating the skin and hair, especially to control dandruff and similar scale forming conditions, whereby the hair is washed with a detergent composition and after rinsing out this is treated consecutively with a separately applicable composition with an acid pH in the absence of detergents, by which microbial growth is inhibited through both treatments.

In particular the hair is washed with a detergent composition containing a combination of non-irritating detergents as well as amphoteric materials counteracting irritation, if desired together with viscosity modifying materials as well as suitable substances to prevent dehydration of the skin by the detergent action (so called Rückfetter), whereby in the main embodiment an anti-mycotic is included, being a suitable water soluble anti-mycotic to induce dandruff control. As mentioned no such substances should be used which give rise to microbial resistance.

In the phase I composition one aims at a thorough cleaning of the hair and scalp combined with a skin condition promoting treatment. For this purpose substances are added which are beneficial to the skin, such as the mentioned "Rückfetter", as well as for instance amphoteric substances. It is to be understood that the

phase I treatment is carried out under such circumstances and with such means (thorough cleaning, minimised skin irritation, weakly alkaline pH, as well as the onset of control of fungi) as to promote optimal effect of subsequent phase II treatment.

The invention also provides a two-phase shampoo comprising an integrated shampoo consisting of two compositions, wherein the phase I composition holds a detergent, together with possible cofactors, at a neutral or weakly alkaline pH, and the phase II composition separately from the phase I, comprising a physiologically acceptable acid component which composition is used consecutively, preferably immediately after washing out the phase I composition.

Furthermore, the invention relates to a packaging, for the two-phase shampoo wherein the two compositions are integrated in one package.

To a limited extend shampoo compositions with an acid pH (for instance by including citric acid) are already known, but it has been found that soaps are not well suited for making lower pH products (Cosmetics & Toiletries, volume 95, May 1980, page 9). Thus the simultaneous action of the two previously mentioned compositions included in one shampoo is practically not feasible.

It is assumed that the substance of the corneum (the protein keratin) through a normal alkaline shampoo obtains a "woolly" stereochemically open surface structure, which is advantageous for cleansing but also promotes reinfections and/or growth of established skin flora. This has as a consequence for instance that dandruff is quickly reestablished and is returning regularly irrespective of the treatment with such a shampoo.

It has been found that by a subsequent second treatment with an acid rinsing liquid surface proteins of the skin can be made to coagulate by which they obtain a "closed" stereochemically densely clustered structure (among others as a consequence of the formation of hydrogen bridges); at the same time a more natural pH is obtained. By this one achieves that renewed formation of dandruff etc., which amongst others would be promoted by the open skin structure induced by the alkaline detergent, can be counteracted by the second treatment while also by the acid pH the growth of the head skin flora is further inhibited and irritation reduced.

Several organic acids are used in a dilute solution for various dermatological purposes in view of their antiseptic action. It is further postulated that amongst others the acid component in the phase II treatment penetrates through the pores into the epidermis and absorbed in the skin cells participates with the normal cell metabolism and gives the contemplated favourable biochemical effect. One thus can state that by the phase II treatment the following is reached: 1. an adstringent and anti-irritation effect (stereochemical surface-effect), 2. a biochemical stimulating effect on cellular level after absorption of the component and participation with the intracellular metabolism, and 3. the antiseptic effect of the acid (which is known per se). See in this connection Dermal and Transdermal Absorption, Rainer Brandau, Bärbel H. Lippold, Wissenschaftliche Verlagsgesellschaft m.b.h., Stuttgart, 1982, page 31 and 35 and the Molecular Biology of Skin, P. Mier Ph.Dr., J.D.Cotton, Ph.D., Blackwell 1976, page 57, and "Cosmetics & Toiletries", volume 100, No. 3 (1985), Shampoo documentary.

The phase I composition essentially consists of a detergent, such as normally used in shampoos, selected from the various anionic, kationic, non-ionic or amphoteric detergents and in such a formulation that it is not harmful to the skin. For a survey of these means one is referred to the Handbook of Schwarz, Perry and Berch, Surface Active Agents, published 1958 by Interscience Publishers and in McCutcheon's Detergents and Emulsifiers, 1969 Annual.

In principle any physiologically acceptable, mild detergent, which does not have a directly damaging effect (for instance sensibilisation or toxicity) on the skin or causes damage to the hair and which possesses sufficiently cleansing and dissolving power, is used. Mild detergents in combination with protein condensation products, hydrolysats etc., such as these are commercially available, are preferred.

Good examples are amongst others blends of laurylether sulphate, laurylpolyglycolether sulphosuccinate and fatty acid alkylamides (commercially available as Rewopol (R) of REWO.)

The pH of the phase I composition (also including mixtures, combinations and formulations) is preferably in the neutral or weakly alkaline range. The best results are obtained with a pH between 7,5 and 8,5, but preferably not above 8,5, always with the condition that the activity is physiologically acceptable. The purpose is to further an open structure of the epidermis, as mentioned above, thus enhancing the permeability of the epidermis, so that a detergent, antimycotic or conditioning agent may be used optimally.

Phase I formulation may be a solution, emulsion or suspension, (such as is commonly used for shampoos) where by the consistency may be adjusted by viscosity modifying agents. A good detergent power and a good rinsability is prime objective.

In phase I formulation a conditioner may be included, by which the hair can be brought in such a condition that the phase II treatment has a better cosmetic effect. Gelatin, casein, keratinous compounds, such as albumin proteins, which are physiologically acceptable are preferably used. It has been found that using these substances a thin protein layer remains on the skin and the hair which contributes to the protective effect of the acid treatment as indicated in the beginning.

Examples of the keratinous materials are albumins, such as amongst others lactalbumin and ovalbumin and possibly vegetable matters of that kind. These substances are included in sufficient amounts to obtain the desired effect; normally this amounts to a few per cent, for example 0,5-7,5 per cent by weight of the phase I mixture.

In some cases it is advantageous to make use of the open structure of the skin caused by the phase I treatment through an alcohol to further penetration of effective anti-mycotics into the skin and thus to potentiate phase II action. Also this possibility is of importance in using particular organic acids in the phase II composition, which acids per se possess an anti microbial action, such as fumaric acid and azelaic acid. In this way the effect of the antimycotic in phase I as well as phase II is enhanced!

The phase I composition may contain anti-mycotics in the medicinal as well as the anti-dandruff variant, provided these do not induce resistance as mentioned above. One may use an anti-mycotic substance in combination with albumin or a protein condensation product. An example of such anti-mycotic substance is tar, especially tar soap. Furthermore, anti-mycotics like zinc pyrithion, sulfur and lithium compounds (see British Medical Journal 292, January 1986, page 28) imidazole derivatives (compounds) are acceptable as long^{as} they are used in physiologically acceptable concentrations. Of course one may also use general pharmaceuticals, provided these display a softening or irritation lowering effect.

In a specific embodiment one may use a water soluble anti-mycotic such as piroctone olamine (Hoechst), chemical name 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-(1H)-pyridinone compound with 2-aminoethanol (1:), whereby as mentioned above, the effect in phase I as well as phase II treatment (if carried out with "quats" in the phase II composition), can be optimized. The amounts thereof are resp. between about 1% and 0.2% preferably 1,0% and 0,3% (% based on weight of mixture). One may also use zinc pyridithion in which case it is recommended to use a mixture with disodium undecylenic acid monoethanol amidosulfosuccinate (Rewocid (R) of REWO) which as is known forms a synergistic mixture with zinc pyridithion. Rewocid, the said undecylenic acid derivative as such is useful as well as other sulfosuccinates in phase II as a antimicrobial substance which has a mild effect on the skin, and thus contributes to the control of dandruff.

The phase I composition preferably contains a pH-stabilizer like a pH buffer, by which one achieves that the action as desired by the phase I composition is secured, i.e. the cleansing and rinsing effect as well as the conditioning effect. The advantage of the pH adjustment by means of a buffer of the phase I composition in the alkaline range is that the above action of the detergents can be optimized without damaging side effects (for example extreme alkalinity).

Phase I composition may furthermore contain adjuvants and other additives which are usual for shampoos such as thickeners, preservatives, anti-oxydants, dyes, flavouring agents, opacity promoting, clarifying or sequestering agents as well as foam controlling agents; in the amounts which are usual for these adjuvants. However, it is preferred to use as little as possible of these substances and to balance the compositions within the presently established dermatological limits (see Orfanos Supra) as indicated by our objectives.

The phase II composition contains a solution of a physiologically acceptable organic acid or mixture of these acids. An acid is preferred which participates in the normal cell metabolism. These acids may be saturated or unsaturated, mono or poly basic, especially dibasic organic acids, preferably with 2-16 carbon atoms (branched or linear) which may be substituted with acceptable substituents, like for instance especially the alfa-hydroxy acids. The acids may contain aromatic substituents.

Examples of these acids are acetic, propionic, fumaric, benzoic, maleic, azelaic, citric, salicylic, succinic, pyruvic, glutaric,

malic, lauric, malonic, lactic, undecenic, undecylenic, decane-1, 10-dioic acid and derivatives thereof. Organic acids which are known to give a therapeutic effect in the treatment of skin diseases have preference, like fumaric, azelaic, decane-1,10-dioic, salicylic, acetic, propionic, benzoic, undecylenic, sorbic acid etc.

The acidity of the phase II solution is generally adjusted in the area of pH 3-6, preferred 4-5. The acidity of the phase II composition is adjusted in such a way that after application a situation is reached which is as much as possible in agreement with the natural pH of the skin. This means that since pH regulation takes place on the scalp by biochemical buffer action etc., preference is given to a pH which is slightly below the physiological value, which pH after use of the two phase treatment is adjusted upward to the physiological value. See for this matter Rainer Branday as already mentioned, page 35.

The phase II composition may further contain adjuvants which promote the action of the phase I composition. As such, well known adstringents can be cited, which reinforce the action of the acids and are physiologically acceptable, like aluminium and zinc salts (for example alum and tanning agents like tannin). also epithelium growth promoting substances may be applied like dexpanthenol.

One may further include anti-septic or disinfectant substances, as well as anti-mycotics which are known per se, in so far as these are not taken up in the phase I composition for chemical reasons, like for example undecylene derivative products. Also adjuvants may be utilized like for instance for protective means, epidermal reinforcement or nurturing, cosmetic means, which also includes the usual colouring and flavouring substances, as well as hair growth

stimulating means, like minoxidilum.

One may also use piroctone olamine in phase II because of its anti-seborrhoeic effect. When this is combined with an organic acid with antiseptic properties one obtains an enhanced broad spectrum activity which is of importance because of the relatively short period of duration of a shampoo rinsing treatment compared with a long lasting therapy.

It will be understood that also cosubstances are desired which sustain as much as possible the action contemplated and contribute cosmetically to attractive properties as well. E.g. it is preferred to use as solvent a mixture of water and alcohol which gives a good percutaneous absorption and strengthen the effect of the acid and the antimicrobial agents. Also thickeners can be added, like tylose (hydroxyethyl cellulose) and similar cellulose derivatives.

Thus with the rinsing liquid a pH restoration and hydrogen bonding of the epidermal layer proteins is reached as well as the proteins supplied by means of formulation I, so that a protective action occurs and also a sebo suppressive effect is obtained by which a continued action of pityrosporum yeasts are inhibited. The two formulations of the two-phase shampoo are used in combination and they are suitably packed together but separately, on the one hand because both compositions may not be mixed without loss of effectivity and on the other hand because the synergistic effect of the components used in both liquids is only obtained if they are used one directly after the other! The effect of the phase II formulation thus is only reached when used consecutively and almost directly after the cleansing treatment and water rinsing, but before the head skin flora can recover. After the application of the phase II formulation, as is the case after phase I, rinsing takes place

with water. Through transdermal absorption, however, the phase II composition and its effects on the scalp is maintained sufficiently till the next shampoo treatment, while the excess of components from this formulation on the skinsurface is eliminated by rinsing with water so that also from a cosmetical point of view one has reached a better hair- and skin condition.

The invention thus also comprises packaging modifications wherein both components of the two-phase shampoo are taken up separately but combined in one package. a suitable embodiment is amongst others a plastic container, provided with two juxtapositioned flasks, which container also may be provided with a plastic plate to connect it with an adhesive strip against the wall of the bath room. Both flasks can be separately packaged or for convenience be esthetically combined. For this last purpose one flask in another embodiment is used which contains a separating wall by which two compartments are formed. One may also provide a combined moving or flip opening, or another type of opening, by which firstly the compartment with the detergent (phase I) can be dispensed and thereafter the compartment with the rinsing liquid (phase II). Preferably the containers or compartments are distinguished from each other by size, appearance or other sensory effect (color, consistency, etc. of the components).

Example 1

(Shampoo for psoriasis-like seborrheic dermatitis*).

With a medicinal variation of the two-phase shampoo a treatment was carried out using test persons during several months, wherein

* Shuster (1984) Br. J. Dermatol. 111, page 235

two times a week the hair was washed. The test persons were persons suffering from tenacious dandruff, while one of them suffered from a grave seborrhoeic dermatitis. As a first component of the two-phase treatment one used for this purpose the following composition:

	<u>percentage</u>
Triethanolamine laurylsulphate (detergent)	45
glycerine (clarifyer and conditioner)	5
lauryldiethanolamide (foam booster)	5
buffer and sequestrating agent	0,2
coal tar destillate (Fluxöl ST)	1,5
colouring and perfume with water	to 100%

pH is in the weakly alkaline domain. Fluxöl ST (commercial product) is used because besides its antimycotic action it also has a keratostatic and sebosuppressive action (in the second phase of the treatment the weak tar smell was almost neutralized).

The phase I composition of the two-phase shampoo was supplied on the wet scalp in the normal way and rubbed in.

By means of the composition of this first phase of the scalp-treatment, the deeper resident microflora is reached through the fat dissolving action of the detergent, by which the dermatophytes in the hair follicle and sweat gland pores are eradicated more effectively via the antimycotic action of coal tar destillate.

Thereafter the composition was as usual rinsed out with water. Immediately thereafter in the second phase a head skin-treatment was carried out with a composition with a low pH which for this experiment was formulated as follows:

dexpantenol	2% (epithelium growth promoting factor)
fumaric acid	5% (anti-psoriasis factor)
ethanol	15% (desinfectant)
Al-acetate tartrate	0,2% (adstringent)
lanoline	0,2%
hydroxypropylcellulose	1% (gelling agent)
flavour and colouring materials	
water	to 100%
pH about 3,5	

With this composition complete freedom of the seborrheic constitution was effected and in combination with phase I treatment in due course an effective eradication of the pityrosporum fungus on the head was reached. An exposure time of about 2 minutes in the second phase was sufficient. This was followed by rinsing with water. The epithelium-promoting, antiseptical, pH reducing and adstringent effect of this treatment on the scalp persists by transdermal absorption in the epidermis through pores and corneocytes to a sufficient degree till the next shampoo treatment.

It thus appears that with this two-phase shampoo of the invention already after several weeks an effective control of seborrheic dermatitis and dandruff was obtained.

Example II.

(Conditioning anti-dandruff shampoo)

One starts from a phase I composition in the cosmetic variation with zinc pyrithion as anti-mycotic.

	<u>Percentage</u>
Cocoamphocarboxyglycinate	15 (amphoteric)
Cocoamidepropyl hydroxysulfobetaine	10 (amphoteric)
Sodium lauryl sulphate	15 (detergent)
Lauramide DEA	1 (foam booster)
Cocamine oxyde	1 (foam booster)
Zinc pyrithion (48% dispersion)	3 (anti-mycotic)
Polyquaternium 17 (Mirapol AD-1)	2 (conditioner)
Water, colour and flavour to	100%
pH adjusted to 7,8	

The phase II composition contains an alpha-hydroxy-acid like lactic acid which plays an important physiological role in the structural stability and functional elasticity of the epidermis and keratine proteins.

	<u>Percentage</u>
Allantoine	2 (cosmetic epithelium growth promoting agent)
lactid acid	5 (bacterio and myco- static agent)
Negatol	30 (adstringent)
Methylcellulose	1 (gelling agent)
Flavouring and colouring materials	
water to	100%
pH to 4,5 with NaOH	

The results in this treatment of dandruff were comparable with those of example I; a sound skin with retention of biologically and cosmetically favourable hair properties was obtained.

Similar or even better results were obtained when substituting pirocton olamine for zinc pyrithion (the effective amount of the first is about half of the amount of the latter). It also appears that by having a small amount of quaternary ammonium compounds ("quat") present, the retention of the anti-mycoticum on the skin is enhanced.

Example III

One started with a clear phase I shampoo composition which was specifically formulated to possess in addition to anti-dandruff action also good foaming and conditioning properties.

	<u>Percentage</u>
Cocoamidopropylbetaine	20 (amphoteric)
Sodium laurylsulphate	25 (detergent)
Cocodimoniumcollagene hydrolysate	1 (protein conditioner)
Acetamide MEA	1 (conditioner)
Lithiumsuccinate*	5 (anti-mycotic)
Propylene glycol	} 1 (preserving agents)
Propylene paraben	
Methyl paraben	
Flavouring and colouring materials	
water to	100%
pH 7,5	

* British Medical Journal (1986) 292,28" Use of topical lithium succinate for seborrheic dermatitis".

The phase II composition was formulated according to example I with the exception that fumaric acid was replaced by dodecanedioic acid 8%. The results were comparable.

Example IV

One formulated an eggwhite shampoo as phase I composition as follows.

	<u>Percentage</u>
Sodiumlaurylthiosulphate keratine complex	5%
(this detergent also has an anti-dandruff action)	
Triethanolamine laurylsulphate	10,5% (detergent)
Laurylisopropanolamide	1,5 (conditioner)
Methylparaben	1 (preserving agent)
pH 7,5	

The phase II composition was formulated according to example I with the exception that fumaric acid was replaced by azelaic acid 5%**. Here also a favourable anti-seborrhoic effect was obtained.

Example V

One started from a phase I composition which contained acylated sodium laurylsulphate (20%), as detergent and cocodiethanolamide and anhydrous lanoline (both 0,6%). Furthermore 1% albumine was included as conditioner. In composition I also 1% zinc pyrithion was present with the remainder water. The pH was above 7,5. The phase II composition was 5% acetic acid with, 30% ethanol, thickening agents,

** Ref. British Journal of dermatology (1986), 114,493.

flavouring and colouring materials. During regular use a lasting curative effect was obtained which was promoted by the albumine conditoning agent.

Example VI

The experiment of example I was repeated, however, the phase I anti-fungus component was Omadine 1,5%. Also an effective control of dandruff was obtained.

Example VII

The two-phase shampoo of examples I-VI was held in a carrier fixed to the wall provided with two recesses, in which the respective flasks for compositions I and II fitted, whereby the flask of composition II was congruent with flask I, but larger and with another appearance. The container was connected to the wall by means of an adhesive strip so that one could easily carry out the two-phase treatment.

Example VIII

The two-phase shampoo of examples I-VI was presented in one flask provided with a compartment-forming separating wall and two flipopenings through which compositions I and II could easily and in the right order be delivered from the flask. As in example VII the two-in-one flask was provided with a handy plateau, which could be connected to the wall by means of an adhesive strip.

CLAIMS

- 19 -

1. Process for treating the skin of the head and hair, like a cleansing, conditioning, cosmetical and medicinal treatment whereby the scalp and hair in the first phase is washed with a detergent composition with neutral or alkaline pH and in the second phase after rinsing out of the composition is consecutively treated with a separately applicable composition of acid pH.
2. Process according to claim 1, whereby the phase I treatment is carried out in such a way that the skin of the head and hair are thoroughly cleaned, but additionally are kept in a good condition.
3. Process according to claim 2, whereby in phase I mild detergents together with non-irritating amphoteric substances are used, together with substances which prevent drying out of the skin as a result of excessive defatting.
4. Process according to claims 1-3, whereby especially for medicinal purpose in the phase I and II compositions an antimycotic, especially a water soluble antimycotic is included and in the phase II composition an organic acid is included, especially an acid with an anti-microbial action.
5. Two phase shampoo comprising an integrated formulation consisting of two compositions, wherein the phase I composition contains detergents as well as adjuvants at a neutral or alkaline pH and the phase II composition, separate from the first composition comprises a physiologically acceptable acid component, at a pH of 3-6.

6. Shampoo according to claim 2, wherein the phase I composition comprises a combination of non-irritating detergents, anti-irritating, conditioning and amphoteric substances as well as means preventing drying out of the skin through excessive defatting.
7. Shampoo according to claims 5-6, wherein the phase I composition contains a pH stabilizer and possesses neutral or weak alkaline properties.
8. Shampoo according to claim 7, wherein the pH of the phase II composition is adjusted at 4-6.
9. Shampoo according to claim 8, whereof the pH is about 5.
10. Shampoo according to claims 5-9, whereof the phase I composition contains an antimycotic, especially a soluble antimycotic, provided this does not lead to dermal or systemic toxicity or resistance phenomena.
11. Shampoo according to claim 10, whereof both phase I and II contain antimycotics.
12. Shampoo according to claims 5-11, wherein the phase II composition is a solution of a physiologically acceptable organic acid or mixtures of such acids with a pH stabilizer.
13. Shampoo according to claim 12, wherein the organic acid is selected from acids with a chain length of 2-15 carbon atoms (branched and/or saturated or not and/or containing aromatic groups), which acid also may contain physiologically acceptable substituents.

14. Shampoo according to claims 5-13, where in both phases I and II epithelium promoting agents are included, provided they are not having a sensitizing effect.
15. Shampoo according to claims 5-14, wherein the pH of the phase I composition is in the range of 7,5-8,5.
16. Shampoo according to claims 5-15, where in the phase II composition adstringents are included.
17. Shampoo according to claims 5-16, wherein as antimycotic piroctone olamine is present in both phases.
18. Package according to claims 5-17, wherein both compositions are kept separately in a combination bottle or are packed in two separate flasks.
19. Package according to claim 18, wherein the package is provided with such a slidable, flip or other opening that first composition I and only thereafter composition II can be obtained from the container.
20. Package according to claims 18 and 19, provided with a support and an adhesive strip so that attachment to the wall and storage of one or both flasks therein is possible in a convenient way.

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 87/00372

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 7/08; A 61 K 7/06																																
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System </td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; padding-top: 10px;">IPC⁴</td> <td style="border: none; padding-top: 10px;">A 61 K</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁴	A 61 K																										
Classification System	Classification Symbols																															
IPC ⁴	A 61 K																															
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category ⁹</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">FR, A, 2013680 (L'OREAL) 3 April 1970 see the whole document</td> <td style="vertical-align: top;">1,2,5,7-9, 12-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="text-align: center; vertical-align: top;">--</td> <td style="vertical-align: top;">1-3,5-9,11- 16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">GB, A, 2116218 (WELLA) 21 September 1983 see the whole document</td> <td style="vertical-align: top;">1-3,5-9,12- 16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="text-align: center; vertical-align: top;">--</td> <td style="vertical-align: top;">1-3,5-9,12- 16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">DE, A, 2023159 (FA-L'OREAL) 4 February 1971 see the whole document</td> <td style="vertical-align: top;">1-3,5-9,12- 16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="text-align: center; vertical-align: top;">--</td> <td style="vertical-align: top;">1,2,5,7-9, 12-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">US, A, 4381920 (GARLEN) 3 May 1983 see the whole document</td> <td style="vertical-align: top;">1,2,5,7-9, 12-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">US, A, 4301820 (CANNELL et al.) 24 November 1981 see the whole document</td> <td style="vertical-align: top;">1,2,5,7-9, 12-20</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">--</td> <td style="text-align: right; vertical-align: top;">./.</td> <td></td> </tr> </tbody> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	FR, A, 2013680 (L'OREAL) 3 April 1970 see the whole document	1,2,5,7-9, 12-16	Y	--	1-3,5-9,11- 16	Y	GB, A, 2116218 (WELLA) 21 September 1983 see the whole document	1-3,5-9,12- 16	Y	--	1-3,5-9,12- 16	Y	DE, A, 2023159 (FA-L'OREAL) 4 February 1971 see the whole document	1-3,5-9,12- 16	X	--	1,2,5,7-9, 12-16	X	US, A, 4381920 (GARLEN) 3 May 1983 see the whole document	1,2,5,7-9, 12-16	X	US, A, 4301820 (CANNELL et al.) 24 November 1981 see the whole document	1,2,5,7-9, 12-20	--	./.	
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																														
X	FR, A, 2013680 (L'OREAL) 3 April 1970 see the whole document	1,2,5,7-9, 12-16																														
Y	--	1-3,5-9,11- 16																														
Y	GB, A, 2116218 (WELLA) 21 September 1983 see the whole document	1-3,5-9,12- 16																														
Y	--	1-3,5-9,12- 16																														
Y	DE, A, 2023159 (FA-L'OREAL) 4 February 1971 see the whole document	1-3,5-9,12- 16																														
X	--	1,2,5,7-9, 12-16																														
X	US, A, 4381920 (GARLEN) 3 May 1983 see the whole document	1,2,5,7-9, 12-16																														
X	US, A, 4301820 (CANNELL et al.) 24 November 1981 see the whole document	1,2,5,7-9, 12-20																														
--	./.																															
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																																
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; padding-bottom: 10px;"> Date of the Actual Completion of the International Search 6th October 1987 </td> <td style="width: 50%; border: none; padding-bottom: 10px;"> Date of Mailing of this International Search Report 20 NOV. 1987 </td> </tr> <tr> <td style="width: 50%; border: none; padding-top: 10px;"> International Searching Authority EUROPEAN PATENT OFFICE </td> <td style="width: 50%; border: none; padding-top: 10px;"> Signature of Authorized Officer M. VAN MOL </td> </tr> </table>			Date of the Actual Completion of the International Search 6th October 1987	Date of Mailing of this International Search Report 20 NOV. 1987	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer M. VAN MOL																										
Date of the Actual Completion of the International Search 6th October 1987	Date of Mailing of this International Search Report 20 NOV. 1987																															
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer M. VAN MOL																															

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	EP, A, 0114414 (WELLA) 1 August 1984 see the whole document	1,2,5,7-9, 12-16
	--	
A	US, A, 4344446 (EHRHARDT) 17 August 1982 see the whole document	1-20

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/EP 87/00372 (SA 17758)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 15/10/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2013680	03/04/70	LU-A- 56584	26/01/70
		DE-A- 1937947	03/09/70
		CH-A- 514337	31/10/71
		GB-A- 1279144	28/06/72
		US-A- 3676546	11/07/72
		BE-A- 736388	22/01/70
		DE-A,B,C 2034202	11/02/71
		FR-A,B 2051629	09/04/71
		LU-A- 59072	09/03/71
		CH-A- 525672	31/07/72
		GB-A- 1294500	25/10/72
		CA-A- 961411	21/01/75
		BE-A- 753037	06/01/71
GB-A- 2116218	21/09/83	DE-A,C 3207738	08/09/83
		JP-A- 58162513	27/09/83
DE-A- 2023159	04/02/71	FR-A,B 2042569	12/02/71
		LU-A- 58634	09/03/71
		US-A- 3849576	19/11/74
		US-A- 3879560	22/04/75
		US-A- 3976781	24/08/76
		US-A- 4002671	11/01/77
		US-A- 4151301	24/04/79
		US-A- 4085217	18/04/78
		US-A- 4204064	20/05/80
		US-A- 4394520	19/07/83
US-A- 4381920	03/05/83	None	
US-A- 4301820	24/11/81	US-A- 4424820	10/01/84
EP-A- 0114414	01/08/84	WO-A- 8402842	02/08/84
		DE-A- 3301515	19/07/84
		AU-A- 2344184	15/08/84
		JP-T- 60500210	21/02/85
		CA-A- 1216242	06/01/87
		US-A- 4660580	28/04/87
		AU-B- 563116	25/06/87

For more details about this annex :
see Official Journal of the European Patent Office, No. 12/82

INTERNATIONAL APPLICATION NO.
-----PCT/EP 87/00372 (SA 17758)

US-A- 4344446 17/08/82 None

For more details about this annex :
see Official Journal of the European Patent Office, No. 12/82